These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 16250653)

  • 1. Is antagonism of E/Z-guggulsterone at the farnesoid X receptor mediated by a noncanonical binding site? A molecular modeling study.
    Meyer U; Costantino G; Macchiarulo A; Pellicciari R
    J Med Chem; 2005 Nov; 48(22):6948-55. PubMed ID: 16250653
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic effects of guggul and its constituent guggulsterone: cardiovascular benefits.
    Deng R
    Cardiovasc Drug Rev; 2007; 25(4):375-90. PubMed ID: 18078436
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Guggulsterone activates multiple nuclear receptors and induces CYP3A gene expression through the pregnane X receptor.
    Brobst DE; Ding X; Creech KL; Goodwin B; Kelley B; Staudinger JL
    J Pharmacol Exp Ther; 2004 Aug; 310(2):528-35. PubMed ID: 15075359
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 5Alpha-bile alcohols function as farnesoid X receptor antagonists.
    Nishimaki-Mogami T; Kawahara Y; Tamehiro N; Yoshida T; Inoue K; Ohno Y; Nagao T; Une M
    Biochem Biophys Res Commun; 2006 Jan; 339(1):386-91. PubMed ID: 16300737
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A natural product that lowers cholesterol as an antagonist ligand for FXR.
    Urizar NL; Liverman AB; Dodds DT; Silva FV; Ordentlich P; Yan Y; Gonzalez FJ; Heyman RA; Mangelsdorf DJ; Moore DD
    Science; 2002 May; 296(5573):1703-6. PubMed ID: 11988537
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Back door modulation of the farnesoid X receptor: design, synthesis, and biological evaluation of a series of side chain modified chenodeoxycholic acid derivatives.
    Pellicciari R; Gioiello A; Costantino G; Sadeghpour BM; Rizzo G; Meyer U; Parks DJ; Entrena-Guadix A; Fiorucci S
    J Med Chem; 2006 Jul; 49(14):4208-15. PubMed ID: 16821780
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The hypolipidemic natural product guggulsterone is a promiscuous steroid receptor ligand.
    Burris TP; Montrose C; Houck KA; Osborne HE; Bocchinfuso WP; Yaden BC; Cheng CC; Zink RW; Barr RJ; Hepler CD; Krishnan V; Bullock HA; Burris LL; Galvin RJ; Bramlett K; Stayrook KR
    Mol Pharmacol; 2005 Mar; 67(3):948-54. PubMed ID: 15602004
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Crystal structure of the human LRH-1 DBD-DNA complex reveals Ftz-F1 domain positioning is required for receptor activity.
    Solomon IH; Hager JM; Safi R; McDonnell DP; Redinbo MR; Ortlund EA
    J Mol Biol; 2005 Dec; 354(5):1091-102. PubMed ID: 16289203
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of the bile acid receptor FXR in Barrett's esophagus and enhancement of apoptosis by guggulsterone in vitro.
    De Gottardi A; Dumonceau JM; Bruttin F; Vonlaufen A; Morard I; Spahr L; Rubbia-Brandt L; Frossard JL; Dinjens WN; Rabinovitch PS; Hadengue A
    Mol Cancer; 2006 Oct; 5():48. PubMed ID: 17054793
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Farnesoid X receptor: from structure to potential clinical applications.
    Pellicciari R; Costantino G; Fiorucci S
    J Med Chem; 2005 Aug; 48(17):5383-403. PubMed ID: 16107136
    [No Abstract]   [Full Text] [Related]  

  • 11. Molecular dynamics simulation of the ligand binding domain of farnesoid X receptor. Insights into helix-12 stability and coactivator peptide stabilization in response to agonist binding.
    Costantino G; Entrena-Guadix A; Macchiarulo A; Gioiello A; Pellicciari R
    J Med Chem; 2005 May; 48(9):3251-9. PubMed ID: 15857131
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recognition of LXXLL by ligand binding domain of the Farnesoid X receptor in molecular dynamics simulation.
    Zhang T; Dong XC; Chen MB
    J Chem Inf Model; 2006; 46(6):2623-30. PubMed ID: 17125202
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting farnesoid X receptor for liver and metabolic disorders.
    Fiorucci S; Rizzo G; Donini A; Distrutti E; Santucci L
    Trends Mol Med; 2007 Jul; 13(7):298-309. PubMed ID: 17588816
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design, synthesis, and evaluation of non-steroidal farnesoid X receptor (FXR) antagonist.
    Kainuma M; Makishima M; Hashimoto Y; Miyachi H
    Bioorg Med Chem; 2007 Apr; 15(7):2587-600. PubMed ID: 17292610
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Farnesoid X-activated receptor antagonists from a marine sponge Spongia sp.
    Nam SJ; Ko H; Shin M; Ham J; Chin J; Kim Y; Kim H; Shin K; Choi H; Kang H
    Bioorg Med Chem Lett; 2006 Oct; 16(20):5398-402. PubMed ID: 16905319
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of a lead pharmacophore for the development of potent nuclear receptor modulators as anticancer and X syndrome disease therapeutic agents.
    Lin HR; Abraham DJ
    Bioorg Med Chem Lett; 2006 Aug; 16(16):4178-83. PubMed ID: 16784849
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Farnesol, a mevalonate pathway intermediate, stimulates MCF-7 breast cancer cell growth through farnesoid-X-receptor-mediated estrogen receptor activation.
    Journe F; Laurent G; Chaboteaux C; Nonclercq D; Durbecq V; Larsimont D; Body JJ
    Breast Cancer Res Treat; 2008 Jan; 107(1):49-61. PubMed ID: 17333335
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhancement of genotype 1 hepatitis C virus replication by bile acids through FXR.
    Scholtes C; Diaz O; Icard V; Kaul A; Bartenschlager R; Lotteau V; André P
    J Hepatol; 2008 Feb; 48(2):192-9. PubMed ID: 18096266
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pyrazolidine-3,5-dione derivatives as potent non-steroidal agonists of farnesoid X receptor: virtual screening, synthesis, and biological evaluation.
    Deng G; Li W; Shen J; Jiang H; Chen K; Liu H
    Bioorg Med Chem Lett; 2008 Oct; 18(20):5497-502. PubMed ID: 18815030
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of the Nurr1 ligand-binding domain co-activator interaction surface.
    Volakakis N; Malewicz M; Kadkhodai B; Perlmann T; Benoit G
    J Mol Endocrinol; 2006 Oct; 37(2):317-26. PubMed ID: 17032747
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.